Israeli startup Aidoc, a developer of artificial intelligence (AI)-powered software that analyzes medical images, announced on Wednesday that it received Food and Drug Administration (FDA) clearance for a solution that flags cases of Pulmonary Embolism (PE) in chest scans for radiologists.
Portions of this article were originally reported in NoCamels.com
Aidoc has CE (Conformité Européenne) marking for the identification and triage of pulmonary embolism (PE) in CT pulmonary angiograms, and FDA approval to scan images for brain hemorrhages.
The latest approval came a month after Aidoc secured $27 million in a Series B round led by Square Peg Capital. Founded in 2016 by Guy Reiner, Elad Walach, and Michael Braginsky, the company has raised some $40 million to date.
Aidoc’s technology assists radiologists in expediting problem-spot detection through specific parameters such as neuron-concentration, fluid-flow, and bone-density in the brain, spine, abdomen, and chest. Aidoc says its solutions cut the time from scan to diagnosis for some patients from hours to under five minutes, speeding up treatment and improving prognosis.
“What really excites us about this clearance is that it paves the way towards scalable product expansion,” Walach, who serves as Aidoc CEO, said in a statement. “We strive to provide our customers with comprehensive end-to-end solutions and have put a lot of effort in developing a scalable AI platform.”
Walach said the company has eight more solutions in active clinical trials.